RxDoctor Payments Data

Regina Lahmann

Family · Wilmington, OHNPI 1881979979

Payments from drug & device makers

$723in general payments, 2019–2025

Across 19 payments — averaging $38.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$287
  • Lilly USA, LLC$107
  • Johnson & Johnson$84
  • AbbVie$74
  • Otsuka America Pharmaceutical, Inc.$52
  • Biohaven Pharmaceuticals, Inc.$51
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$71298%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$723 in reported general payments places this provider in the 65th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$39,220
Medicare patients
156
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide85$104,136
OzempicSemaglutide64$83,531
MounjaroTirzepatide54$71,755
RybelsusSemaglutide46$65,947
JardianceEmpagliflozin62$65,280
EliquisApixaban73$56,455
FarxigaDapagliflozin Propanediol38$36,198
Tresiba Flextouch U-200Insulin Degludec14$31,913
XareltoRivaroxaban31$23,154
JanuviaSitagliptin Phosphate20$18,826
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,469
MyrbetriqMirabegron31$14,671
LinzessLinaclotide14$12,919
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$11,506
Breo ElliptaFluticasone/Vilanterol15$10,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$107$175,891139 claims
PfizerEliquis$28$56,45573 claims
AstraZenecaFarxiga, Brilinta$287$41,51750 claims
Johnson & JohnsonXarelto$84$23,15431 claims
AbbVieLinzess$74$12,91914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,812 family providers in Ohio.

Other family in Wilmington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →